About Partners Intelligence Log in →
Connecting Israeli Defense Tech to US Needs
Log in

Sensible Medical

Wearable radar vest (ReDS) for non-invasive lung-fluid measurement

Israel
51-200

Vitality Radar

63
Current
Industry
Updated 14 days ago

Pillar Analysis

Presence
Digital footprint, brand visibility, and online reach across channels
63
Business
Revenue signals, funding status, partnerships, and market traction
66
Innovation
R&D activity, patents, product launches, and technology adoption
84
Pulse
Recent momentum — hiring trends, news mentions, and social engagement
44
Capacity
Team strength, leadership depth, and organizational scale
58

Strategic Assessment

Strategic Vector

Sensible Medical is a focused medtech company pursuing a niche, clinically oriented growth path around non-invasive lung-fluid monitoring for heart failure, with evidence of U.S. commercial presence and regulated product positioning.[1][2][5][18] Its strongest signal is technical differentiation rooted in defense-origin radar sensing, but its public-facing footprint and apparent scale remain modest relative to the maturity of its core technology.[4][11][12]

Efficiency Ratio

The company appears to generate meaningful technical and regulatory output with a relatively small team, suggesting above-average resource efficiency for a niche medtech vendor.[4][9][16]

Evidence Signals

Product Launch HIGH CONF undated

ReDS Pro was announced as the next-generation lung-fluid management product for heart failure.

View source
Partnership HIGH CONF undated

Boston Scientific led a $20M financing round, indicating strategic validation from a major medtech incumbent.

View source Israel
Certification HIGH CONF undated

ReDS received FDA 510(k) clearance and CE mark for thoracic fluid status monitoring.

View source
Expansion HIGH CONF undated

LinkedIn lists dual operating locations in Netanya, Israel and Raleigh, North Carolina, showing a cross-border commercial footprint.

View source Israel; United States
Other MEDIUM CONF undated

The company describes ReDS as originating from defense 'see-through-walls' radar technology, indicating a dual-use technology lineage.

View source Israel
Other HIGH CONF undated

Public company profiles place headcount in the mid-30s to low-50s range, consistent with a small but established operating company.

View source
Other HIGH CONF undated

The website and about page emphasize chronic disease management, non-invasive monitoring, and reduction of hospital readmissions, showing a clear clinical value proposition.

View source

About
Israeli medical-device company (HQ Netanya, Israel; commercial offices in the US), founded in 2007 by Amir Ronen. Its ReDS / SensiVest system is a non-invasive, wearable radar vest that measures lung fluid in ~90 seconds for heart-failure management — technology directly adapted from the Israeli military's 'see-through-wall' radar used to locate people in rubble. FDA 510(k)-cleared (2015) and CE-marked, with the ReDS Pro system contracted onto the US Federal Supply Schedule; licensed to Bayer in Europe and distributed in the US via Medicure. A rare defense-to-medical spinout — the RF/radar lineage is a genuine defense-tech hook within C12.
Tags
#radar #lungfluid #heartfailure #reds #seethroughwall #wearable #fda #dualuse #defenseorigin

Suggest an edit

Footer

Connecting Israeli Defense Tech to US Needs

Powered by Meschonomy

Terms Privacy Contact